Overview of Biseptol 480 mg
Quick Facts
| Property | Description |
|---|---|
| Active Ingredients | Sulfamethoxazole (SMX) and Trimethoprim (TMP) |
| Form | Oral Tablet (most common strength) |
| Pharmacological Class | Broad-Spectrum Antibacterial Agent |
| Primary Classification | Fixed-Dose Combination (FDC) |
| Origin | Synthetic Compound |
What Type of Medication is Biseptol 480 mg?
Biseptol 480 mg is a synthetic, prescription-only, fixed-dose combination medication, globally recognized by the generic name Co-trimoxazole or TMP-SMX. It is definitively classified as a broad-spectrum antibacterial agent, designed to control the proliferation of susceptible microscopic organisms. Its function as a chemically synthesized chemotherapeutic product, rather than a naturally derived antibiotic, is clinically recognized for providing effective microbial control in targeted scenarios. This agent is routinely prescribed when a dependable, multi-spectrum approach is necessary to halt bacterial activity.
The Active Composition of Biseptol 480 mg
The clinical activity of the drug relies on its two active ingredients: Sulfamethoxazole (SMX), a component from the sulfonamide class, and Trimethoprim (TMP), a derivative of the diaminopyrimidine group. The oral tablet form is typically manufactured with the two components in a fixed ratio of 5 parts SMX to 1 part TMP. This specific 480 mg strength refers to the total combined weight of the active ingredients in the oral tablet. The product is typically presented as a plain, scored tablet designed for ease of oral administration in adult patient groups.
General Purpose and Benefit of this Combination
The general therapeutic purpose of Co-trimoxazole is to control and halt the growth of susceptible bacteria through a synergistic bacteriostatic effect. This dual-action mechanism involves interrupting two separate, vital steps in the bacterial production of genetic and structural materials. This unique sequential blockade strategy allows the body to effectively manage and clear the non-replicating bacterial population, which is the foundational benefit underlying its use for common bacterial challenges.
Regulatory References





